Everest Medicines Future Growth
Future criteria checks 5/6
Everest Medicines is forecast to grow earnings and revenue by 80.2% and 38.5% per annum respectively. EPS is expected to grow by 80.4% per annum. Return on equity is forecast to be -5.9% in 3 years.
Key information
80.2%
Earnings growth rate
80.4%
EPS growth rate
| Biotechs earnings growth | 35.6% |
| Revenue growth rate | 38.5% |
| Future return on equity | -5.9% |
| Analyst coverage | Good |
| Last updated | 01 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,418 | 16 | -229 | N/A | 3 |
| 12/31/2025 | 1,522 | -151 | -317 | -198 | 6 |
| 12/31/2024 | 673 | -623 | -1,214 | -862 | 5 |
| 12/31/2023 | 126 | -844 | 545 | -769 | N/A |
| 9/30/2023 | 73 | -424 | 610 | -925 | N/A |
| 6/30/2023 | 21 | -3 | 675 | -1,082 | N/A |
| 3/31/2023 | 17 | -125 | -174 | -1,119 | N/A |
| 12/31/2022 | 13 | -247 | -1,024 | -1,156 | N/A |
| 9/30/2022 | 7 | -770 | -1,479 | -1,006 | N/A |
| 6/30/2022 | 1 | -1,294 | -1,934 | -857 | N/A |
| 3/31/2022 | 1 | -1,151 | -1,820 | -793 | N/A |
| 12/31/2021 | 0 | -1,009 | -1,706 | -730 | N/A |
| 9/30/2021 | 0 | -3,213 | -1,238 | -685 | N/A |
| 6/30/2021 | N/A | -5,418 | -770 | -640 | N/A |
| 3/31/2021 | N/A | -6,154 | -1,092 | -582 | N/A |
| 12/31/2020 | N/A | -5,658 | -992 | -472 | N/A |
| 3/31/2020 | N/A | -10 | -271 | -126 | N/A |
| 12/31/2019 | N/A | -215 | -182 | -89 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1952 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: 1952 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 1952 is expected to become profitable in the next 3 years.
Revenue vs Market: 1952's revenue (38.5% per year) is forecast to grow faster than the Hong Kong market (7.6% per year).
High Growth Revenue: 1952's revenue (38.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1952 is forecast to be unprofitable in 3 years.